NeuroSense TherapeuticsNRSN
About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Employees: 16
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 7 [Q2] → 7 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
8.11% less ownership
Funds ownership: 9.27% [Q2] → 1.16% (-8.11%) [Q3]
85% less capital invested
Capital invested by funds: $1.87M [Q2] → $286K (-$1.59M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for NRSN.
Financial journalist opinion
Based on 4 articles about NRSN published over the past 30 days